ethyl 2-[({[(2-hydroxyethyl)aMino]carbonyl}oxy)Methyl]-5,7-diMethyl-3-{2-[(MethylaMino)sulfonyl]phenyl}-4-oxo-3,4-dihydroquinazoline-6-carboxylate manufacturers
- SAD-448
-
- $2580.00
-
2026-05-11
- CAS:581106-09-4
- Purity:
- Supply Ability: 10g
|
| | ethyl 2-[({[(2-hydroxyethyl)aMino]carbonyl}oxy)Methyl]-5,7-diMethyl-3-{2-[(MethylaMino)sulfonyl]phenyl}-4-oxo-3,4-dihydroquinazoline-6-carboxylate Basic information |
| | ethyl 2-[({[(2-hydroxyethyl)aMino]carbonyl}oxy)Methyl]-5,7-diMethyl-3-{2-[(MethylaMino)sulfonyl]phenyl}-4-oxo-3,4-dihydroquinazoline-6-carboxylate Chemical Properties |
| | ethyl 2-[({[(2-hydroxyethyl)aMino]carbonyl}oxy)Methyl]-5,7-diMethyl-3-{2-[(MethylaMino)sulfonyl]phenyl}-4-oxo-3,4-dihydroquinazoline-6-carboxylate Usage And Synthesis |
| Uses | SAD448 is a CB1 and CB2 receptor agonist. SAD448 can lower intraocular pressure (IOP)[1]. | | References | [1] Pryce G, et al. Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J. 2014 Jan;28(1):117-30. DOI:10.1096/fj.13-239442 |
| | ethyl 2-[({[(2-hydroxyethyl)aMino]carbonyl}oxy)Methyl]-5,7-diMethyl-3-{2-[(MethylaMino)sulfonyl]phenyl}-4-oxo-3,4-dihydroquinazoline-6-carboxylate Preparation Products And Raw materials |
|